Tirzepatide for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a weight-loss medication called tirzepatide in teenagers who are overweight or obese and have other health problems related to their weight. The study will last about two years and involve multiple visits. Tirzepatide is effective in treating obesity in patients with and without diabetes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are taking any medications or supplements for weight loss, you must stop them at least 90 days before joining the study.
Is tirzepatide safe for humans?
How is the drug Tirzepatide unique for treating obesity?
Tirzepatide is unique because it combines two actions in one drug, targeting both the GLP-1 and GIP receptors, which helps with significant weight loss and improves other health markers like blood pressure and insulin sensitivity. This dual action makes it more effective than other treatments that only target one receptor.16789
What data supports the effectiveness of the drug Tirzepatide for obesity?
Research shows that Tirzepatide, a drug that works on specific hormones in the body, helps people with obesity and type 2 diabetes lose weight effectively. Studies found that it leads to more weight loss compared to other similar treatments and also improves other health factors like blood pressure and insulin sensitivity.69101112
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adolescents with obesity (BMI ≥95th percentile) or overweight with weight-related issues like high cholesterol, high blood pressure, liver disease, sleep apnea, or prediabetes. Those treated for Type 2 Diabetes with diet/exercise or metformin can join if their HbA1c is below 9.0%.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tirzepatide or placebo subcutaneously once weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tirzepatide
Tirzepatide is already approved in United States, European Union, Canada, United Kingdom for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University